Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 214

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability

Open access
Lee, Tae-Hee, Avraham, Hava Karsenty, Jiang, Shuxian, Avraham, Shalom·2003·Journal of Biological Chemistry
DOI 10.1074/jbc.m210063200
Open this paper in CoChat — free account

Abstract

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), has been shown to increase potently the permeability of endothelium and is highly expressed in breast cancer cells. In this study, we investigated the role of VEGF/VPF in breast cancer metastasis to the brain. Very little is known about the role of endothelial integrity in the extravasation of breast cancer cells to the brain. We hypothesized that VEGF/VPF, having potent vascular permeability activity, may support tumor cell penetration across blood vessels by inducing vascular leakage. To examine this role of VEGF/VPF, we used a Transwell culture system of the human brain microvascular endothelial cell (HBMEC) monolayer as an in vitro model for the blood vessels. We observed that VEGF/VPF significantly increased the penetration of the highly metastatic MDA-MB-231 breast cancer cells across the HBMEC monolayer. We found that the increased transendothelial migration (TM) of MDA-MB-231 cells resulted from the increased adhesion of tumor cells onto the HBMEC monolayer. These effects (TM and adhesion of tumor cells) were inhibited by the pre-treatment of the HBMEC monolayer with the VEGF/VPF receptor (KDR/Flk-1) inhibitor, SU-1498, and the calcium chelator 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (acetoxymethyl)ester. These treatments of the HBMEC monolayer also inhibited VEGF/VPF-induced permeability and the cytoskeletal rearrangement of the monolayer. These data suggest that VEGF/VPF can modulate the TM of tumor cells by regulating the integrity of the HBMEC monolayer. Taken together, these findings indicate that VEGF/VPF might contribute to breast cancer metastasis by enhancing the TM of tumor cells through the down-regulation of endothelial integrity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m210063200

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 49

  1. Orr, 2000, J. Pathol., 190, 310, 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P · doi:10.1002/(sici)1096-9896(200002)190:3<310::aid-path525>3.0.co;2-p
  2. Nicolson, 1994, Oncogenesis, 5, 451, 10.1615/CritRevOncog.v5.i5.20 · DOI
  3. Nicolson, 1988, Cancer Metastasis Rev., 7, 143, 10.1007/BF00046483 · DOI · Paper page
  4. Akiyama, 1995, Cancer Metastasis Rev., 14, 173, 10.1007/BF00690290 · DOI · Paper page
  5. Thurston, 1999, Science, 286, 2511, 10.1126/science.286.5449.2511 · DOI · Paper page
  6. Thurston, 2000, Nat. Med., 6, 460, 10.1038/74725 · DOI · Paper page
  7. Olesen, 1986, Brain Res., 368, 24, 10.1016/0006-8993(86)91038-3 · DOI
  8. Tanno, 1992, J. Neurotrauma, 9, 335, 10.1089/neu.1992.9.335 · DOI
  9. Ikeda, 1995, J. Biol. Chem., 270, 19761, 10.1074/jbc.270.34.19761 · DOI · Paper page
  10. Gleadle, 1995, Am. J. Physiol., 268, C1362, 10.1152/ajpcell.1995.268.6.C1362 · DOI · Paper page
  11. Neufeld, 1999, FASEB J., 13, 9, 10.1096/fasebj.13.1.9 · DOI · Paper page
  12. Ferrara, 1997, Endocr. Rev., 18, 4, 10.1210/edrv.18.1.0287 · DOI · Paper page
  13. Brekken, 2000, Cancer Res., 60, 5117
  14. Senger, 1986, Cancer Res., 46, 5629
  15. Brown, 1995, Hum. Pathol., 26, 86, 10.1016/0046-8177(95)90119-1 · DOI · Paper page
  16. Berkman, 1993, J. Clin. Invest., 91, 153, 10.1172/JCI116165 · DOI · Paper page
  17. Boocock, 1995, J. Natl. Cancer Inst., 87, 506, 10.1093/jnci/87.7.506 · DOI · Paper page
  18. Bachelder, 2001, Cancer Res., 61, 5736
  19. Lee, 2002, J. Biol. Chem., 277, 10445, 10.1074/jbc.M107348200 · DOI · Paper page
  20. Gospodarowicz, 1986, J. Cell. Physiol., 127, 121, 10.1002/jcp.1041270116 · DOI · Paper page
  21. De Jong, 1998, J. Pathol., 184, 53, 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7 · DOI · Paper page
  22. Friesel, 1995, FASEB J., 9, 919, 10.1096/fasebj.9.10.7542215 · DOI · Paper page
  23. Kramer, 1980, Int. J. Cancer., 26, 639, 10.1002/ijc.2910260516 · DOI · Paper page
  24. Dejana, 1999, Exp. Cell Res., 252, 13, 10.1006/excr.1999.4601 · DOI · Paper page
  25. Honn, 1989, FASEB J., 3, 2285, 10.1096/fasebj.3.11.2673900 · DOI
  26. Kusama, 1995, Int. J. Cancer., 63, 112, 10.1002/ijc.2910630120 · doi:10.1002/ijc.2910630120
  27. Lewalle, 1998, Clin. Exp. Metastasis, 16, 21, 10.1023/A:1006555800862 · doi:10.1023/a:1006555800862
  28. Curry, 1992, FASEB J., 6, 2456, 10.1096/fasebj.6.7.1563597 · doi:10.1096/fasebj.6.7.1563597
  29. Morel, 1990, Inflammation, 14, 571, 10.1007/BF00914277 · DOI
  30. van Nieuw Amerongen, 1998, Circ. Res., 83, 1115, 10.1161/01.RES.83.11.1115 · DOI · Paper page
  31. Bates, 1997, Am. J. Physiol., 273, H687, 10.1152/ajpcell.1997.273.2.C687 · DOI
  32. Kevil, 1998, J. Biol. Chem., 273, 15099, 10.1074/jbc.273.24.15099 · DOI · Paper page
  33. Huang, 1993, J. Cell Biol., 120, 1371, 10.1083/jcb.120.6.1371 · DOI · Paper page
  34. Ziegelstein, 1994, Circulation, 90, 1899, 10.1161/01.CIR.90.4.1899 · DOI
  35. Pfau, 1995, J. Cell Biol., 128, 969, 10.1083/jcb.128.5.969 · DOI
  36. Etienne-Manneville, 2000, J. Immunol., 165, 3375, 10.4049/jimmunol.165.6.3375 · DOI · Paper page
  37. Kim, 2001, J. Biol. Chem., 276, 7614, 10.1074/jbc.M009705200 · DOI · Paper page
  38. Kim, 2001, Circ. Res., 89, 477, 10.1161/hh1801.097034 · DOI · Paper page
  39. Brodt, 1997, Int. J. Cancer., 71, 612, 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D · doi:10.1002/(sici)1097-0215(19970516)71:4<612::aid-ijc17>3.0.co;2-d
  40. Laferriere, 2001, J. Biol. Chem., 276, 33762, 10.1074/jbc.M008564200 · doi:10.1074/jbc.m008564200
  41. Nagayasu, 1998, Br. J. Cancer., 77, 1371, 10.1038/bjc.1998.229 · DOI
  42. Shibata, 2000, Tumour Biol., 21, 299, 10.1159/000030135 · doi:10.1159/000030135
  43. Gehlsen, 1988, J. Cell Biol., 106, 925, 10.1083/jcb.106.3.925 · DOI · Paper page
  44. Yi, 2001, Proc. Natl. Acad. Sci. U. S. A., 98, 620, 10.1073/pnas.98.2.620 · DOI · Paper page
  45. Fujita, 1992, Jpn. J. Cancer Res., 83, 1317, 10.1111/j.1349-7006.1992.tb02764.x · DOI
  46. Miralem, 2001, Oncogene, 20, 5511, 10.1038/sj.onc.1204753 · DOI
  47. Price, 2001, Cell Growth Differ., 12, 129
  48. Gerber, 2002, Nature, 417, 954, 10.1038/nature00821 · DOI · Paper page
  49. Melnyk, 1996, Cancer Res., 56, 921

Cited by

See all 214

Metadata

Authors
Lee, T.-H., Avraham, H. K., Jiang, S., & Avraham, S.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2003-02
Volume
278
Issue
7
Pages
5277-5284
ISSN
0021-9258 (ISSN-L)
DOI
10.1074/jbc.m210063200
OpenAlex
W1995042765
Cited by
214
References
1
FWCI
3.00
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability. https://app.cochat.ai/papers/10.1074/jbc.m210063200
The paper
Lee, T.-H., Avraham, H. K., Jiang, S., & Avraham, S. (2003). Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m210063200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.